These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29567722)
1. Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid? Masini T; Hauser J; Kuwana R; Nhat Linh N; Jaramillo E Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567722 [No Abstract] [Full Text] [Related]
2. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439 [No Abstract] [Full Text] [Related]
3. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging. Li Y; Sun F; Zhang W Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290 [TBL] [Abstract][Full Text] [Related]
4. Using bedaquiline and delamanid in combination and safely. Dedicoat M Int J Tuberc Lung Dis; 2016 Oct; 20(10):1282. PubMed ID: 27725032 [No Abstract] [Full Text] [Related]
5. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276 [TBL] [Abstract][Full Text] [Related]
6. Progress in global rollout of new multidrug-resistant tuberculosis treatments. Held K; McAnaw S; Chiang CY; Trebucq A; Horsburgh CR Int J Tuberc Lung Dis; 2019 Sep; 23(9):996-999. PubMed ID: 31615606 [No Abstract] [Full Text] [Related]
7. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc? Shah I; Gandhi S; Shetty NS Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176 [TBL] [Abstract][Full Text] [Related]
8. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Reuter A; Tisile P; von Delft D; Cox H; Cox V; Ditiu L; Garcia-Prats A; Koenig S; Lessem E; Nathavitharana R; Seddon JA; Stillo J; von Delft A; Furin J Int J Tuberc Lung Dis; 2017 Nov; 21(11):1114-1126. PubMed ID: 29037291 [TBL] [Abstract][Full Text] [Related]
9. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942 [TBL] [Abstract][Full Text] [Related]
10. Tuberculosis treatment and drug regimens. Sotgiu G; Centis R; D'ambrosio L; Migliori GB Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017822. PubMed ID: 25573773 [TBL] [Abstract][Full Text] [Related]
11. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied? Cox V; Furin J Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439 [TBL] [Abstract][Full Text] [Related]
12. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367 [TBL] [Abstract][Full Text] [Related]
13. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199 [TBL] [Abstract][Full Text] [Related]